{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:45:26Z","timestamp":1756464326008,"version":"3.40.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"am","delay-in-days":332,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clgc.2024.102236","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T20:23:49Z","timestamp":1728505429000},"page":"102236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Appearance of New Lesions Associate With Poor Prognosis in Pembrolizumab-Treated Urothelial Carcinoma"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-2815","authenticated-orcid":false,"given":"Takuto","family":"Hara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Teishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyoshi","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Bando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4447-6516","authenticated-orcid":false,"given":"Tomoaki","family":"Terakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoji","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzo","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2024.102236_bib0001","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102236_bib0002","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102236_bib0003","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102236_bib0004","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/17588359221096877","article-title":"Immune-related dissociated response as a specific atypical response pattern in solid tumors with immune checkpoint blockade","volume":"14","author":"Guan","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clgc.2024.102236_bib0005","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related responsecriteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2024.102236_bib0006","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2020.02.016","article-title":"A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation","volume":"131","author":"Lala","year":"2020","journal-title":"Eur. J. Cancer."},{"key":"10.1016\/j.clgc.2024.102236_bib0007","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102236_bib0008","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2024.102236_bib0009","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely-available easy-to-use software \"EZR\" (Easy R) for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clgc.2024.102236_bib0010","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.128728","article-title":"Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy","volume":"4","author":"Winters","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.clgc.2024.102236_bib0011","first-page":"1","article-title":"Differences in tumor immune microenvironment in metastatic sites of breast cancer","volume":"11","author":"Lee","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.clgc.2024.102236_bib0012","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41525-017-0013-8","article-title":"Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma","volume":"2","author":"Reuben","year":"2017","journal-title":"NPJ Genom. Med."},{"key":"10.1016\/j.clgc.2024.102236_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.cji.0000211341.88835.ae","article-title":"Cancer Vaccine Clinical Trial Working Group. A clinical development paradigm for cancer vaccines and related biologics","volume":"30","author":"Hoos","year":"2007","journal-title":"J Immunother"},{"key":"10.1016\/j.clgc.2024.102236_bib0014","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-13-0895","article-title":"Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements","volume":"19","author":"Nishino","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2024.102236_bib0015","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.clgc.2024.102236_bib0016","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/iju.15231","article-title":"The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion","volume":"30","author":"Hara","year":"2023","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2024.102236_bib0017","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00262-021-03000-8","article-title":"Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR","volume":"71","author":"Kobayashi","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clgc.2024.102236_bib0018","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.annonc.2021.09.006","article-title":"Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab","volume":"32","author":"Topp","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clgc.2024.102236_bib0019","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/iju.12766","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: a multi-institutional study","volume":"22","author":"Taguchi","year":"2015","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2024.102236_bib0020","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/cas.14762","article-title":"Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab","volume":"112","author":"Kobayashi","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clgc.2024.102236_bib0021","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clgc.2024.102236_bib0022","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/iju.15435","article-title":"Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: a retrospective multicenter study in Japan","volume":"31","author":"Hara","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2024.102236_bib0023","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102236_bib0024","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102236_bib0025","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102236_bib0026","doi-asserted-by":"crossref","DOI":"10.1111\/iju.15528","article-title":"Comparative clinical trials with a novel approach: utilizing the shiny method for investigational urothelial carcinoma therapies","author":"Hara","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2024.102236_bib0027","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102236_bib0028","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T16:44:45Z","timestamp":1746463485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324002064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1558767324002064"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102236","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Appearance of New Lesions Associate With Poor Prognosis in Pembrolizumab-Treated Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102236","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102236"}}